Utilization of surfactant assisted zinc oxide nanodisk against breast cancer cells
Source abstract
Abstract
The current work displayed the efficacy of the nanodisk shaped zinc oxide nanostructures (NDs-ZnONSs) processed via hydrothermal solution process and studies the cytotoxicity against human breast cancer cells (MCF-7). The NDs-ZnONSs were analyzed by using instruments such as X-ray diffraction pattern (XRD), Field emission scanning electron microscopy (FESEM), and Fourier transform infra-red spectroscopy (FTIR). The XRD and FESEM shows the crystallinity and morphology of NDs-ZnONSs states the estimated width size of each sheet diameter and length are ∼20-25 nm and 2-3 µm respectively. The cytotoxicity of MCF-7 cells with NDs-ZnONSs at different concentrations (1, 2, 5, 10, 25, 50 and 100 µg/mL) were examined via MTT and NRU assays. The results showed that at initial (1, 2 and 5 µg/ml) concentrations of NDs-ZnONSs didn’t show any cytotoxicity in cancer cells but higher concentrations (25, 50 and 100 µg/mL) of NDs-ZnONSs displayed a remarkable inhibition in cancer cells growth and morphology. Further, the reactive oxygen species (ROS) generation was also examined with NDs-ZnONSs at different concentrations and result showed that it increased with increasing the concentration of NDs-ZnONSs in MCF-7 cells. The expression of apoptotic genes (p53, bax, casp-3) including control via qRT-PCR, reveals that mRNA level of apoptotic genes with NDs-ZnONSs were upregulated.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticles: synthesis and applications · Magnesium Oxide Properties and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biology, College of Science, University of Hafr Al Batin, Hafr Al Batin, Saudi Arabia
References (24)
Show source-provided references
1. 10.1016/j.synthmet.2009.08.00610.1016/j.synthmet.2009.08.006 ↗
2. 10.1016/j.cap.2010.07.03010.1016/j.cap.2010.07.030 ↗
3. 10.1016/j.arabjc.2017.05.01110.1016/j.arabjc.2017.05.011 ↗
4. 10.1016/j.cej.2011.01.03810.1016/j.cej.2011.01.038 ↗
5. 10.1016/j.cej.2011.09.05510.1016/j.cej.2011.09.055 ↗
6. 10.1016/j.spmi.2018.09.02110.1016/j.spmi.2018.09.021 ↗
7. 10.2174/156652401366613111113005810.2174/1566524013666131111130058 ↗
8. 10.1007/s40820-015-0040-x10.1007/s40820-015-0040-x ↗
9. 10.1016/j.colsurfa.2019.12395310.1016/j.colsurfa.2019.123953 ↗
10. 10.1016/j.diamond.2016.01.01210.1016/j.diamond.2016.01.012 ↗
11. 10.1038/s41598-020-57532-710.1038/s41598-020-57532-7 ↗
12. 10.1016/j.onano.2022.10008210.1016/j.onano.2022.100082 ↗
13. 10.1016/j.materresbull.2006.11.03510.1016/j.materresbull.2006.11.035 ↗
14. 10.1016/j.apsusc.2007.03.06010.1016/j.apsusc.2007.03.060 ↗
15. 10.1007/s10876-021-02013-810.1007/s10876-021-02013-8 ↗
16. 10.1016/j.procbio.2020.07.02610.1016/j.procbio.2020.07.026 ↗
17. 10.1007/s10856-011-4405-510.1007/s10856-011-4405-5 ↗
18. 10.1016/j.jbiotec.2021.01.02210.1016/j.jbiotec.2021.01.022 ↗
19. 10.1016/j.matlet.2016.05.06710.1016/j.matlet.2016.05.067 ↗
20. 10.1016/j.tiv.2008.07.00110.1016/j.tiv.2008.07.001 ↗
21. 10.1016/j.jksus.2021.10165810.1016/j.jksus.2021.101658 ↗
22. 10.3390/app1115670910.3390/app11156709 ↗
23. 10.1007/s10876-017-1215-z10.1007/s10876-017-1215-z ↗
24. 10.3390/nano503116310.3390/nano5031163 ↗